New drug UX016 aims to strengthen muscles in rare disease
NCT ID NCT07511556
First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a new drug called UX016 in 24 adults with GNE myopathy, a rare muscle-weakening disease. The main goals are to check if the drug is safe and if it can improve muscle strength. Participants will receive either UX016 or a placebo, and researchers will measure changes in muscle function and walking ability over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GNE MYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
Orange, California, 92868, United States
-
Clinical Trial Site
Iselin, New Jersey, 08830, United States
Conditions
Explore the condition pages connected to this study.